Hybridoma Center / Monoclonal Antibody Development Core

Two pipelines of services are available for 1) development of custom monoclonal antibodies and 2) generation of lipid nanoparticles (LNP) encapsulating designated payloads.

1. The Hybridoma Center / Monoclonal Antibody Development Core assists investigators in the custom generation of monoclonal antibody producing B cell hybridomas. Guidance is provided in the selection of appropriate model species, immunogen format, development of immunization strategies, multi-tiered screening protocols and methods for antibody production. Immunization services are available for mouse (wild type, genetically engineered or autoimmune) and Armenian hamster models. Conventional (protein or cellular), genetic (plasmid DNA), and payload-containing LNP (mRNA) immunization platforms are available. Once sufficient antibody titers are identified from immune animals, splenocytes are fused with a murine myeloma and cell cultures are maintained in the Core facility. Hybridoma culture supernatants are harvested and screened for the presence of antigen reactive antibody. The Hybridoma Center can provide ELISA based screening, however, more sophisticated assays are performed by individual investigators. Hybridomas secreting antigen-specific antibodies are subcloned by limiting dilution to establish a stable cell line secreting a unique antibody with defined specificity and isotype. Mycoplasma screening and mAb isotype services are available. Hybridoma stabilization and cell line optimization are provided for large scale expansion. Cell banks are generated and are returned to the investigator or may be stored long-term within the Core facility. All materials generated remain the property of the investigator.
2. New technology within the Hybridoma Center allows for production of research grade lipid nanoparticles (LNP) with encapsulation of a variety of payloads. Our Ignite NanoAssemblr system provides an easy-to-use microfluidic platform to enable controlled and precise assembly of LNP, suitable for in vitro and in vivo use in pre-clinical studies. Services are provided by core staff or training can be arranged for self-use of the instrumentation. This reproducible system can generate up to 20 ml of LNP. QC of particles may include mRNA quantitation and determination of encapsulation efficiency (Ribogreen assay) and particle size (Dynamic Light Scattering).

Service available to All entities, including for-profit organizations.

Priority service for All entities, including for-profit organizations.

Additional information:

Contracted services are open to non-University organizations on a fee for service basis.

In vivo immunization services and in vitro cell culture services are provided.

Payload encapsulation into LNP services and QC available.

• Antibody development: consultation for immunization methods and screening strategies
• Immunization of mice (wild type, genetically engineered or autoimmune) or Armenian hamsters
• Conventional, genetic hydrodynamic immunization (plasmid DNA) or LNP (mRNA) immunization
• B cell fusion for monoclonal antibody development
• ELISA-based supernatant screening
• Hybridoma subcloning, cell line optimization and isotype analysis
• Cryopreservation and long-temr banking
• LNP: consultation on lipid nanoparticle production
• Staff-provided generation of payload encapsulated (drug, mRNA, etc.) LNP
• Training for self-use of Ignite NanoAssemblr
• QC of LNPs - quantitation, size and efficiency (Ribogreen assay and Dynamic Light Scattering analysis)

• Full cell culture suite
• LN2 cryostorage facility
• PNI Ignite NanoAssemblr

Please contact this core directly for pricing information.